• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

The following list of names for the drugs described are "under consideration" by the USAN Council:

August 2014

barbarlizumab treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis
blontuvetmab veterinary antineoplastic
critegumab treatment of diabetes
dolcanatide treatment of GI disorder; inflammatory bowel disease
ruclosporin treatment of dry eye and canine keratoconjunctivitis siccac
sagnezumab treatment of Alzheimer’s disease
tactuvetmab veterinary antineoplastic

July 2014

bexagliflozin treatment of diabetes
ciraparantag reversal of anticoagulation
daprodustat treatment of anemia, diabetic wounds and reduction of ischemic complications
netarsudil treatment of glaucoma or ocular hypertension
nirucumab treatment of age-related macular degeneration
noblituzumab antineoplastic
onstancizumab treatment of diabetes, halting the progression of diabetic nephropathy
pacadostat treatment of cancer
ramantinib treatment of cancer
refnezumab treatment for the recovery of motor function after stroke
tavilermin dry eye disease
tezlepelumab treatment of asthma and atopic dermatitis
velansorsen treatment of familial chylomicronemia syndrome
vidranumab prevention of migraine
vuretraxin prevention and treatment of scarring

June 2014

aglatimagene beradenovac antineoplastic
domeglicant treatment of diabetes
doncanatide treatment of GI disorder; inflammatory bowel disease
pegmodglutide treatment of diabetes and/or obesity
scrinvacumab antineoplastic
susquetide reduce intensity and duration of tissue damage caused by inflammation cascade and mucositis, increase clearance of bacterial infection
tofeglicant treatment of diabetes